Form 4: Edwards Lifesciences Director Michael Mussallem Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Michael Mussallem exercised stock options and sold shares of Edwards Lifesciences Corp. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Mussallem, a director at Edwards Lifesciences Corp, executed a transaction involving the company's stock on May 2, 2024.
• Mussallem exercised employee stock options to acquire 29,350 shares at a price of $36.75 per share.
• Concurrently, Mussallem sold 12,207 shares at a weighted average price of $85.02 and 17,143 shares at a weighted average price of $84.59.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 15, 2023.
• Following these transactions, Mussallem directly owns 4,485.82 shares and indirectly owns 4,038,377 shares through a living trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There's no indication of positive or negative outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and orderly approach to stock transactions.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and the use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of illegal insider trading.
• Comparable companies such as Medtronic, Abbott Laboratories, and Boston Scientific also see regular Form 4 filings from their executives and directors.
• The size and frequency of these transactions can vary widely based on individual circumstances and company policies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they reflect insider selling, but the existence of a 10b5-1 plan mitigates concerns about opportunistic trading.

Key Dates